Hemispherx Biopharma, Inc. (AMEX: HEB) today announced
that David R. Strayer, MD, Medical Director, will be a presenter at
the Rodman & Renshaw 3rd Annual Global Healthcare in Monte Carlo,
Monaco on May 15 at 10:50 AM CEST. A live webcast of this presentation
will be available via the Company's website at www.hemispherx.net. An
archived presentation will be available for 90 days.
Dr. Strayer will review the Company's progress and achievements in the last several months, including a review of audited data from the Phase III clinical trials for the experimental immuno-stimulant Ampligen's(R) application to Chronic Fatigue Syndrome (CFS). The data from Hemisherx Biopharma arrives shortly after the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, reported that its own studies show that CFS has a biological and genetic basis. The CDC report, which CDC Director Julie Gerberding called "groundbreaking," provides further evidence that a combination of genetic predisposition and environmental factors can induce CFS.
New data will be reviewed from global clinical and animal studies that are being conducted with the company's experimental products Ampligen(R) and Alferon LDO (Low Dose Oral) for potential treatment against avian influenza. The studies, conducted in Hong Kong, Japan, Canada and the United States, utilize Alferon LDO as a stand-alone antiviral and Ampligen co-administered as an immunostimulant with vaccines and antivirals.
Friday, May 12, is National Awareness Day for fibromyalgia and CFS. The national observance recognizes the many government agencies, research institutions, academic institutions and drug developers working together to find a better way to cope with the diseases and the resulting economic impact, estimated to be in excess of $9 billion annually. Hemispherx Biopharma is contributing to this movement by sponsoring clinical research and plans to file the first NDA for the formal treatment of CFS with Ampligen(R) during 2006.
About Hemispherx
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx Biopharma's flagship products include Alferon(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). Alferon(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(TM) represent experimental nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon(R) N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R), Alferon(R) LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.
Dr. Strayer will review the Company's progress and achievements in the last several months, including a review of audited data from the Phase III clinical trials for the experimental immuno-stimulant Ampligen's(R) application to Chronic Fatigue Syndrome (CFS). The data from Hemisherx Biopharma arrives shortly after the U.S. Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia, reported that its own studies show that CFS has a biological and genetic basis. The CDC report, which CDC Director Julie Gerberding called "groundbreaking," provides further evidence that a combination of genetic predisposition and environmental factors can induce CFS.
New data will be reviewed from global clinical and animal studies that are being conducted with the company's experimental products Ampligen(R) and Alferon LDO (Low Dose Oral) for potential treatment against avian influenza. The studies, conducted in Hong Kong, Japan, Canada and the United States, utilize Alferon LDO as a stand-alone antiviral and Ampligen co-administered as an immunostimulant with vaccines and antivirals.
Friday, May 12, is National Awareness Day for fibromyalgia and CFS. The national observance recognizes the many government agencies, research institutions, academic institutions and drug developers working together to find a better way to cope with the diseases and the resulting economic impact, estimated to be in excess of $9 billion annually. Hemispherx Biopharma is contributing to this movement by sponsoring clinical research and plans to file the first NDA for the formal treatment of CFS with Ampligen(R) during 2006.
About Hemispherx
Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based disorders. Hemispherx Biopharma's flagship products include Alferon(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). Alferon(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(TM) represent experimental nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon(R) N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net
Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R), Alferon(R) LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.